Abstract Background Extramedullary involvement of B-cell Acute Lymphoblastic Leukemia (EM-ALL) is a rare occurrence. characterized by dismal outcome and the absence of a defined and shared therapeutic approach. In the landscape of innovative compounds. inotuzumab ozogamicin (IO) is a promising drug. https://www.markbroyard.com/super-save-whole-wheat-phyllo-pastry-sheets-jufka-sa-integralnim-brasnom-12pcs-x-450g-jami-supply-great-choice/